Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
2-APB (HB1208)
Description:IP3 receptor and store-operated channels (SOC) channel antagonist
Purity:>98%
Alprenolol hydrochloride (HB1734)
Description:Non-selective β-adrenoceptor antagonist. Also a 5-HT1A receptor antagonist.
Purity:>99%
AM251 (HB2776)
Description:Potent, selective CB1 receptor antagonist / inverse agonist
Purity:>98%
AM281 (HB2312)
Description:Potent, selective CB1 receptor antagonist / inverse agonist
Purity:>98%
Amantadine hydrochloride (HB0109)
Description:Non-competitive NMDA receptor antagonist
Purity:>98%
AMD 3100 octahydrochloride (HB2739)
Description:Potent, selective CXCR4 antagonist. Mobilizes hematopoietic stem cells.